Scalper1 News
Big-cap biotech Vertex Pharmaceuticals (VRTX) was down 4% in morning trading today after the results on its latest cystic fibrosis drug disappointed investors. Vertex reported data from a midstage study combining drug candidate VX-661 with the already-marketed ivacaftor, branded Kalydeco, in patients with cystic fibrosis caused by homozygous F508del mutation. As IBD reported in our roundup of upcoming clinical-trial news last week, Vertex’s other Scalper1 News
Scalper1 News